{
    "id": 27519,
    "fullName": "ERBB2 G776_V777insVGC",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) G776_V777insVGC results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insVGC has not been characterized, however other exon 20 insertions are activating thus, G776_V777insVGC is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).",
            "references": [
                {
                    "id": 1980,
                    "pubMedId": 23220880,
                    "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23220880"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2004,
                    "pubMedId": 16843263,
                    "title": "HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16843263"
                },
                {
                    "id": 2002,
                    "pubMedId": 17311002,
                    "title": "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17311002"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "G776_V777insVGC",
    "createDate": "03/15/2018",
    "updateDate": "03/15/2018",
    "referenceTranscriptCoordinates": {
        "id": 170514,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724748_39724749insAGGTTGTGT",
        "cDna": "c.2330_2331insAGGTTGTGT",
        "protein": "p.G778_S779insCVG",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13251,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 1 patient and progressive disease in 2 patients with non-small cell lung cancer harboring ERBB2 (HER2) G776_V777insVGC (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 29037,
                "profileName": "ERBB2 G776_V777insVGC"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29037,
            "profileName": "ERBB2 G776_V777insVGC",
            "profileTreatmentApproaches": [
                {
                    "id": 18538,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 G776_V777insVGC"
                },
                {
                    "id": 18537,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 G776_V777insVGC"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170515,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724748_39724749insAGGTTGTGT",
            "cDna": "c.2330_2331insAGGTTGTGT",
            "protein": "p.G778_S779insCVG",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170514,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724748_39724749insAGGTTGTGT",
            "cDna": "c.2330_2331insAGGTTGTGT",
            "protein": "p.G778_S779insCVG",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}